Trial Profile
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2024
Price :
$35
*
At a glance
- Drugs Alectinib (Primary) ; Brigatinib (Primary) ; Ceritinib (Primary) ; Crizotinib (Primary) ; Ensartinib (Primary) ; Lorlatinib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Carcinoma; Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Acronyms NCI-NRG ALK Protocol
- 05 Dec 2023 Number of treatment arms are increased from 7 to 10 by the addition of separate experimental arms for 3 mutations namely- ALK L1198F mutation, L1196 mutation and No ALK-resistance mutations.
- 16 Nov 2023 Planned End Date changed from 11 Apr 2024 to 21 Sep 2024.
- 13 Apr 2023 Planned End Date changed from 19 May 2023 to 11 Apr 2024.